Anbio Biotechnology (NNNN) vs Q/C Technologies (QCLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Anbio Biotechnology is the larger company by market cap ($204.5 million vs $5.2 million), about 39.6 times the size. On valuation, Q/C Technologies trades at a lower trailing P/E (0.2x vs 31.1x for Anbio Biotechnology).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NNNN | QCLS |
|---|---|---|
| Share price | $4.66 | $0.63 |
| Market cap | $204.53M | $5.16M |
| 1-day change | +0.87% | -1.05% |
| YTD return | -84.64% | — |
| 1-year return | -85.09% | — |
| P/E ratio (TTM) | 31.07 | 0.24 |
| EPS (TTM) | $0.15 | $2.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $44.73 | $8.17 |
| 52-week low | $4.20 | $0.42 |
| Distance from 52-week high | -89.58% | -92.29% |
| Average volume | 146.84K | 4.98M |
| Shares outstanding | 43.89M | 8.19M |
| Employees | 27 | 3 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Anbio Biotechnology is about 39.6 times larger than Q/C Technologies by market value ($204.53M vs $5.16M).
- Anbio Biotechnology trades at a higher earnings multiple (31.1x vs 0.2x trailing P/E).
About Anbio Biotechnology
NNNN stock →Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 27 employees
About Q/C Technologies
QCLS stock →Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 3 employees
NNNN vs QCLS FAQ
Which is bigger, Anbio Biotechnology or Q/C Technologies?
Anbio Biotechnology (NNNN) is larger, with a market capitalization of $204.53M compared with $5.16M for Q/C Technologies (QCLS).
Which has the lower P/E ratio, NNNN or QCLS?
QCLS has the lower trailing P/E at 0.2, versus 31.1 for NNNN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Anbio Biotechnology and Q/C Technologies in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.